Search Results

You are looking at 321 - 330 of 1,423 items for :

  • "characteristics" x
  • Refine by Access: All x
Clear All
Full access

P. Connor Johnson, Netana H. Markovitz, Tamryn F. Gray, Sunil Bhatt, Ryan D. Nipp, Nneka Ufere, Julia Rice, Matthew J. Reynolds, Mitchell W. Lavoie, Carlisle E.W. Topping, Madison A. Clay, Charlotta Lindvall, and Areej El-Jawahri

characteristics along with healthcare utilization and mortality. To investigate the relationship between social support and OS, we conducted Cox proportional hazards regression analyses, adjusting for the following covariates that were a priori defined based on

Full access

Tejaswi Mudigonda, Daniel J. Pearce, Brad A. Yentzer, Phillip Williford, and Steven R. Feldman

physicians, and $521 for other physicians. 28 Table 2 Treatment Characteristics of Non–Melanoma Skin Cancer Episodes in 1999–2000 by Specialty To further illustrate treatment characteristics according to specialty, Manternach et al. 27

Full access

Sriram Yennurajalingam, Vicente Valero, Zhanni Lu, Diane D. Liu, Naifa L. Busaidy, James M. Reuben, Carolina Diaz Fleming, Janet L. Williams, Kenneth R. Hess, Karen Basen-Engquist, and Eduardo Bruera

interventions, along with tolerability. To compare patient characteristics, we used the chi-square and the Wilcoxon signed rank tests for the FACIT-F (primary outcome), ESAS fatigue item, PROMIS-F, MFSI-SF, ESAS physical distress score, ESAS psychological

Full access

Tammy T. Hshieh, Clark DuMontier, Timothy Jaung, Nupur E. Bahl, Chelsea E. Hawley, Lee Mozessohn, Richard M. Stone, Robert J. Soiffer, Jane A. Driver, and Gregory A. Abel

on information extracted from the oncology consultation note. Statistical Analysis Population characteristics were summarized using proportions. Chi-square analyses were performed in the total population to assess for associations between

Full access

Characteristics (N=35) Conclusions: Interim results show high pCR rates compared with those reported with anthracyclines/taxanes in TNBC. Pretreatment biopsies will be analyzed for predictive markers. An ongoing randomized study is evaluating the

Full access

Stephanie Alimena, Suvidya Lakshmi Pachigolla, Sarah Feldman, David Yang, Peter F. Orio III, Larissa Lee, and Martin King

not if aged ≥65 years (11.7% vs 12.4%; P =.43). Figure 1 shows differences in private insurance, stage I disease, and optimal treatment among Black versus non-Black patients by age. Table 1. Demographic and Treatment Characteristics of the Study

Full access

Omar Abdel-Rahman, Hatim Karachiwala, and Jacob C. Easaw

, extrahepatic spread, and macrovascular invasion. Variables chosen in the logistic and Cox models were based on their possible correlation with opioid intake and the possible relationship to outcomes in this patient cohort. Results Patient Characteristics A

Full access

Neal Andruska, Benjamin W. Fischer-Valuck, Ruben Carmona, Temitope Agabalogun, Randall J. Brenneman, Hiram A. Gay, Jeff M. Michalski, and Brian C. Baumann

,559 (61%) received LDR-BT, 432 (7%) received HDR-BT, and 1,847 (32%) received BT not otherwise specified. Baseline characteristics among men stratified by treatment with EBRT or BT are summarized in Table 1 . The average age of men receiving EBRT versus

Full access

David E. Gerber, Thomas Y. Sheffield, M. Shaalan Beg, Erin L. Williams, Valerie L. Clark, Yang Xie, M.E. Blair Holbein, Celette Sugg Skinner, and Simon J. Craddock Lee

applying the Fisher exact test to contingency tables. Results A total of 94 of 108 (87%) survey recipients completed the survey. Characteristics of these individuals are shown in Table 1 . As would be expected given the high response rate, there

Full access

Anthony A. Matthews, Sharon Peacock Hinton, Susannah Stanway, Alexander R. Lyon, Liam Smeeth, Krishnan Bhaskaran, and Jennifer L. Lund

generally small. Table 1. Baseline Characteristics of Study Cohorts Primary Analyses Mean follow-up per person ranged from 3.73 years in the valvular heart disease analysis to 4.50 years in the pulmonary embolism analysis. Incident rates of cardiovascular